Credits: Social Media
Weight loss drug Mounjaro ‘significantly’ more effective than Ozempic, study finds
A study has found that despite its popularity, Ozempic isn’t actually the most effective weight loss drug out there.
Ozempic, which was originally designed as a treatment for people with type 2 diabetes, first blew up in 2021 for its ability to help people lose weight, but one other drug on the market could actually be better.
Study finds Mounjaro is more effective than Ozempic
The study, published in JAMA Internal Medicine, compared the effects of semaglutide vs tirzepatide on weight loss.
Semaglutide is the medication used in Ozempic and Wegovy, which are both manufactured by�Novo Nordisk. Tirzepatide is sold under the brand name Mounjaro, another diabetes medication which is known for its weight loss capabilities.
Both semaglutide and tirzepatide aid weight loss in the same way, by mimicking a hormone called GLP-1 that is naturally released in the gastrointestinal tract after we eat,�Harvard Health�explains.
- MORE WEIGHT LOSS: Move over Ozempic, theres a weight loss solution on the horizon that is literally electric
This helps you know when you feel full, thus stopping you from eating more. It also slows down the time it takes for the stomach to empty, helping you feel fuller for longer and decreasing your appetite. Both of these things cause you to eat less and lose weight.
However, the study found that despite doing the same thing, the use of tirzepatide was “associated with significantly greater weight loss than semaglutide”.
18,386 overweight people�taking either semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data from various different US healthcare systems.
The patients receiving tirzepatide showed more weight lost at 3 months (-5.9% body weight vs -3.6%), 6 months (-10.1% vs -5.8%) and 12 months (-15.3% vs -8.3%) in comparison to those injecting semaglutide.
So, the study suggests that Mounjaro is more effective at inducing weight loss than Ozempic and Wegovy. Read about one woman’s experience with Mounjaro.
More about weight loss drug Mounjaro
Mounjaro has been approved for weight loss in both the US and UK. Britain sells it under the same name, while America uses a new name specifically for weight loss rather than type 2 diabetes, Zepbound. Both are the same drug and produced by Eli Lilly.
The injectable prescription medicine may help overweight adults “lose weight and keep it off” when used alongside a reduced-calorie diet and increased physical activity, the Zepbound website says.
While it has been authorized for use in weight loss, there are some possible serious side effects to be aware of including stomach problems, kidney problems, gallbladder problems, pancreatitis, allergic reactions, low blood sugar, depression and changes in vision in patients with type 2 diabetes.
In studies in rats, tirzepatide was also found to cause thyroid tumors. It’s not known if it has the same effect in humans, but people with a history of thyroid cancer�in their family are not advised to use the medication.
More common side effects include nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn.�
- ANOTHER OZEMPIC STUDY: Ozempic also promotes weight loss by speeding up your metabolism, new study suggests
